STOCK TITAN

PDS Biotechnology Corporation - PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

PDS Biotechnology Corporation (Nasdaq: PDSB) is a clinical stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and infectious diseases. The company's proprietary Versamune® platform leverages synthetic and biodegradable lipids to form nanoparticles that are readily taken up by the immune system. These nanoparticles are designed to activate and direct the immune system to target and eliminate disease-causing cells.

PDS Biotech's lead product candidates include PDS0101, targeting HPV-related cancers, and PDS01ADC, an IL-12 fused antibody drug conjugate. These candidates are part of the company's broader strategy to treat a range of cancers, including head and neck, prostate, breast, cervical, and anal cancers.

Recent achievements include the completion of a Phase 1 clinical trial for PDS0101 and ongoing Phase 2 trials demonstrating positive survival results and tumor shrinkage. The company is preparing to initiate a pivotal clinical trial in advanced head and neck cancers in 2024.

Financially, PDS Biotech reported a net loss of $10.8 million for Q3 2023, primarily due to increased R&D and administrative expenses. Despite this, the company remains focused on advancing its pipeline and has several key partnerships to support its research and development efforts.

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its participation in the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 15, 2022. The presentation will cover updates on four PDS0101 phase 2 clinical trials, including studies on head and neck cancer and HPV-associated cancers, in collaboration with prominent institutions like MERCK & Co. and MD Anderson Cancer Center. Additionally, updates on two investigational products and the company’s Infectimune™ pipeline will be shared. A webcast replay will be available post-conference on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced preliminary safety data from its VERSATILE-002 Phase 2 trial, evaluating PDS0101 in combination with KEYTRUDA for treating recurrent or metastatic HPV16-positive head and neck cancer. The trial involved 18 patients and showed no significant toxicity or dose-limiting toxicities. The study's accrual is ongoing, with promising preliminary efficacy results already reported. The company is also conducting additional clinical studies for various HPV-related cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
none
-
Rhea-AI Summary

PDS Biotechnology Corporation (PDSB) has initiated an Investigator-Initiated Trial (ITT) for PDS0101, evaluating its efficacy alone and in combination with KEYTRUDA® in treating HPV-associated oropharyngeal cancer (HPV(+)OPSCC). This study, led by Mayo Clinic, aims to explore neoadjuvant treatment before surgery. HPV(+)OPSCC cases have been rising, with over 54,000 new occurrences expected annually in the US. PDS0101, a part of the Versamune® platform, is designed to enhance anti-tumor responses, potentially leading to better patient outcomes and understanding of the treatment's effectiveness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) has announced that its VERSATILE-002 Phase 2 study has achieved preliminary efficacy milestones for treating advanced HPV-associated head and neck cancer. The trial, evaluating PDS0101 in combination with Merck’s KEYTRUDA, will proceed with full enrollment of 54 patients after successfully demonstrating a tumor response in 4 out of the first 17 patients. This milestone underscores the potential of the Versamune platform to enhance CD8+ T-cell responses. Detailed results are expected to be shared at an upcoming medical conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced promising preclinical results for its universal flu vaccine, PDS0202, which utilizes the Infectimune™ and COBRA technologies. The vaccine demonstrated effective neutralization against multiple influenza strains, potentially offering long-lasting protection that could eliminate the need for yearly vaccinations. Conducted in collaboration with leading immunology experts, the studies showed robust immune responses, including the induction of memory T-cells. These advancements mark significant progress in the company's pipeline addressing infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
-
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022. The presentation will update on three ongoing phase 2 clinical trials involving PDS0101, in collaboration with MERCK & Co., targeting head and neck cancer. Other trials include studies for advanced HPV-associated cancers and locally advanced cervical cancer, led by NCI and MD Anderson Cancer Center respectively. Additionally, updates on PDS0102 and PDS0103, focusing on various cancers, will be provided. A webcast replay will be available post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced that initial safety data from its VERSATILE-002 study will be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium on February 24-26, 2022. This Phase 2 study examines PDS0101 in combination with Merck’s KEYTRUDA for treating recurrent HPV16-positive head and neck cancer. The initial results have met the safety benchmark in the first 12 patients. PDSB is also engaged in further clinical studies for advanced HPV-associated cancers in collaboration with notable institutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary

PDS Biotechnology Corporation has received a granted U.S. patent for PDS0101, extending patent protection until October 2037. This immunotherapy combines the Versamune technology with protein fragments from the HPV16 virus, aimed at inducing T-cell responses against HPV16-related cancers. With over 40,500 annual diagnoses of HPV16-associated cancers, the company is optimistic about its early Phase 2 clinical trial results. PDS Biotech is collaborating with Merck to evaluate PDS0101 in combination with KEYTRUDA for head and neck cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced its management will present at the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. The presentation will cover updates on three ongoing Phase 2 clinical trials for PDS0101 and the progression of PDS0102 and PDS0103 into human trials. A pre-recorded presentation will be available on January 10 at 7:00 am ET. Investors can register for the conference HERE.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences
Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) announced on December 20, 2021, that it granted an inducement equity award of 20,000 shares to Michael Lalond, the new Director of Quality Assurance. This grant, valued at an exercise price of $8.87 per share, is part of Mr. Lalond's employment compensation. The shares vest over four years, with the first quarter vesting on December 20, 2022. PDS Biotech focuses on developing immunotherapies using its proprietary Versamune® technology to enhance immune response against various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
none

FAQ

What is the current stock price of PDS Biotechnology Corporation (PDSB)?

The current stock price of PDS Biotechnology Corporation (PDSB) is $1.64 as of December 24, 2024.

What is the market cap of PDS Biotechnology Corporation (PDSB)?

The market cap of PDS Biotechnology Corporation (PDSB) is approximately 61.4M.

What is PDS Biotechnology Corporation's main area of focus?

PDS Biotechnology focuses on developing next-generation immunotherapies for cancer and infectious diseases using its proprietary Versamune® platform.

What is the Versamune® platform?

The Versamune® platform uses synthetic and biodegradable lipids to form nanoparticles that activate and direct the immune system to target disease-causing cells.

Which cancers are targeted by PDS Biotechnology's therapies?

PDS Biotechnology's therapies target various cancers including head and neck, prostate, breast, cervical, and anal cancers.

What are the recent achievements of PDS Biotechnology?

Recent achievements include completing a Phase 1 clinical trial for PDS0101 and ongoing successful Phase 2 trials showing positive results.

How did PDS Biotechnology perform financially in Q3 2023?

PDS Biotechnology reported a net loss of $10.8 million for Q3 2023, mainly due to higher research and development and administrative expenses.

What is PDS01ADC?

PDS01ADC is an IL-12 fused antibody drug conjugate in development for use in PDS Biotechnology's cancer immunotherapy treatments.

What upcoming events should investors watch?

Investors should watch for the pivotal clinical trial in advanced head and neck cancers planned for 2024.

What are the unique features of PDS Biotechnology's vaccines?

PDS Biotechnology's vaccines induce robust neutralizing antibodies and powerful T-cell responses, including long-lasting memory T-cells.

Where can investors find more information about PDS Biotechnology?

Investors can find more information on the company's official website at www.pdsbiotech.com.

How can the media contact PDS Biotechnology?

Media can contact PDS Biotechnology through Gina Mangiaracina at 6 Degrees via phone at +1 (917) 797-7904 or email at gmangiaracina@6degreespr.com.

PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

PDSB Stock Data

61.35M
36.02M
3.99%
12.36%
12.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON